Technical Analysis for COCP - Cocrystal Pharma, Inc.

Grade Last Price % Change Price Change
grade D 2.17 -1.11% -0.02
COCP closed down 1.11 percent on Wednesday, August 21, 2019, on 2.75 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical COCP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -1.11%
50 DMA Resistance Bearish -1.11%

Older signals for COCP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Medicine Biotechnology Biology Influenza Microbiology Antiviral Drug Virus HCV Biocides Influenza Viruses
Is COCP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.28
52 Week Low 1.51
Average Volume 5,498
200-Day Moving Average 2.6913
50-Day Moving Average 2.2367
20-Day Moving Average 2.3362
10-Day Moving Average 2.4273
Average True Range 0.219
ADX 24.42
+DI 21.2545
-DI 15.4647
Chandelier Exit (Long, 3 ATRs ) 2.293
Chandelier Exit (Short, 3 ATRs ) 2.667
Upper Bollinger Band 2.7316
Lower Bollinger Band 1.9408
Percent B (%b) 0.29
BandWidth 33.849842
MACD Line 0.0169
MACD Signal Line 0.0527
MACD Histogram -0.0358
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.67
Resistance 3 (R3) 2.70 2.58 2.58
Resistance 2 (R2) 2.58 2.45 2.56 2.55
Resistance 1 (R1) 2.37 2.37 2.31 2.34 2.53
Pivot Point 2.25 2.25 2.22 2.23 2.25
Support 1 (S1) 2.04 2.12 1.98 2.01 1.81
Support 2 (S2) 1.92 2.04 1.90 1.79
Support 3 (S3) 1.71 1.92 1.76
Support 4 (S4) 1.68